Warfarin Management in Elderly Patients with a Therapeutic INR

Therapeutic INR Range

For most indications—including atrial fibrillation, venous thromboembolism, and most mechanical heart valves—the target INR is 2.0 – 3.0, with an optimal midpoint of 2.5 (American College of Cardiology). 3
Bleeding risk remains low until the INR exceeds 3.5, and clinically significant hemorrhage becomes a concern primarily when the INR is > 5.0 (Practical Clinical Guidelines). 1

In stable patients, re‑check the INR after 4 weeks (American Geriatrics Society). 5
If the patient has recently entered the therapeutic range or had a dose change, repeat the INR in 1–2 weeks until stability is confirmed (American Geriatrics Society). 5
Once the INR has been stable in the therapeutic range for at least 1 month, a monthly monitoring interval is appropriate (American Geriatrics Society). 6
Elderly patients experience greater INR variability during acute illness or medication changes and therefore merit more frequent monitoring (American Geriatrics Society). 6

Review recent medication changes—especially antibiotics, high‑dose acetaminophen, over‑the‑counter drugs, or herbal supplements—that can alter warfarin metabolism (American Geriatrics Society). 5
Assess alterations in dietary vitamin K intake, such as increased consumption of leafy greens or vitamin K‑containing supplements (American Geriatrics Society). 5
Investigate intercurrent illnesses that affect hepatic or renal function, thyroid status, or cause fever/stress, as these can shift INR values (American Geriatrics Society). 5
Verify medication adherence, since missed doses are common in older adults and may cause INR instability (Practical Clinical Guidelines). 7

Do not reduce the warfarin dose unless the INR is persistently > 3.0 on multiple consecutive measurements (Practical Clinical Guidelines). 1
Do not reduce the dose if a single INR exceeds 3.5 (Practical Clinical Guidelines). 1
Do not reduce the dose when new high‑bleeding‑risk factors appear (e.g., addition of antiplatelet therapy, acute renal impairment, significant anemia, or a new bleeding episode) (Practical Clinical Guidelines). 1
If a future INR falls between 3.0 and 3.5, decrease the weekly warfarin dose by approximately 10 % and re‑check the INR after one week (Practical Clinical Guidelines). 1

Patients ≥ 65 years old generally require lower maintenance doses—often < 5 mg daily—due to increased pharmacodynamic sensitivity (American Geriatrics Society). 6
Even at therapeutic INR levels, elderly patients have a higher risk of intracranial and gastrointestinal hemorrhage (American Geriatrics Society; American College of Cardiology). 8
Age alone does not mandate dose reduction when the INR is therapeutic and stable (Practical Clinical Guidelines). 1

Do not administer vitamin K for an INR of 2.3; reserve vitamin K for INR > 5.0 in asymptomatic patients or for active bleeding (Practical Clinical Guidelines). 1
Do not “chase” isolated INR values that remain within the therapeutic range by making unnecessary dose adjustments, as this creates instability (Practical Clinical Guidelines). 1